(GIST OF SCIENCE REPORTER) Nipah Monoclonal antibodies trial

(JULY-2024)

India may begin human clinical trials for a novel Nipah monoclonal antibody, MBP1F5, in 2025, following regulatory approval. A similar trial will also be conducted in Bangladesh.
Nipah virus has a high mortality rate of 40% to 75%, with recent outbreaks reported in Kerala, India, and widespread infections in Bangladesh since 2001
The novel monoclonal antibody is in phase-1 trials in the U.S., led by the U.S. Department of Defence. These trials are funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
Preclinical studies have shown the antibody to be highly potent against Nipah virus and safe at all tested doses. It binds to the Nipah virus F protein, preventing the virus from entering a host cell.
This antibody offers protection for at least six months, covering both known strains of Nipah and the Hendra virus, ensuring time for vaccine immunity to develop.